Compare RFL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFL | CUE |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 27.1M |
| IPO Year | 2017 | 2017 |
| Metric | RFL | CUE |
|---|---|---|
| Price | $1.35 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 77.8K | ★ 355.6K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.28 | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | $917,000.00 | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 43.96 | ★ 69.16 |
| 52 Week Low | $1.12 | $0.23 |
| 52 Week High | $3.19 | $1.17 |
| Indicator | RFL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 62.90 | 44.87 |
| Support Level | $1.30 | $0.28 |
| Resistance Level | $1.44 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 49.99 | 40.41 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.